Benralizumab

From WikiMD.org
Jump to navigation Jump to search

Benralizumab

Benralizumab (pronunciation: ben-ra-li-zu-mab) is a monoclonal antibody medication used for the treatment of severe eosinophilic asthma. It is marketed under the brand name Fasenra by AstraZeneca.

Etymology

The name "Benralizumab" is derived from the International Nonproprietary Names (INN), where "zu" denotes humanized, "li" indicates immunomodulator, "mab" stands for monoclonal antibody, and "Benra" is a unique stem.

Mechanism of Action

Benralizumab works by binding to the interleukin-5 receptor (IL-5Rα) on the surface of eosinophils and basophils. This binding leads to apoptosis (cell death) of these cells through antibody-dependent cell-mediated cytotoxicity (ADCC).

Usage

Benralizumab is used as an add-on maintenance treatment in patients with severe eosinophilic asthma who are aged 12 years and older, and who are inadequately controlled with their current asthma medicines.

Side Effects

Common side effects of Benralizumab include headache, sore throat, and fever. Serious side effects may include allergic reactions, such as anaphylaxis.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski